947 related articles for article (PubMed ID: 16039863)
21. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
Gangjee A; Vasudevan A; Queener SF
J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.
Li H; Fang F; Liu Y; Xue L; Wang M; Guo Y; Wang X; Tian C; Liu J; Zhang Z
Bioorg Med Chem; 2018 May; 26(9):2674-2685. PubMed ID: 29691154
[TBL] [Abstract][Full Text] [Related]
23. Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
Gangjee A; Devraj R; McGuire JJ; Kisliuk RL
J Med Chem; 1995 Sep; 38(19):3798-805. PubMed ID: 7562910
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
Rosowsky A; Papoulis AT; Forsch RA; Queener SF
J Med Chem; 1999 Mar; 42(6):1007-17. PubMed ID: 10090784
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
Gangjee A; Zeng Y; McGuire JJ; Mehraein F; Kisliuk RL
J Med Chem; 2004 Dec; 47(27):6893-901. PubMed ID: 15615538
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
27. Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
Gangjee A; Zhu Y; Queener SF; Francom P; Broom AD
J Med Chem; 1996 Apr; 39(9):1836-45. PubMed ID: 8627607
[TBL] [Abstract][Full Text] [Related]
28. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1997 Oct; 40(22):3694-9. PubMed ID: 9357537
[TBL] [Abstract][Full Text] [Related]
29. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
[TBL] [Abstract][Full Text] [Related]
30. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF
J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
Gangjee A; Shi J; Queener SF; Barrows LR; Kisliuk RL
J Med Chem; 1993 Oct; 36(22):3437-43. PubMed ID: 8230134
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid as an antifolate.
Gangjee A; Zeng Y; McGuire JJ; Kisliuk RL
J Med Chem; 2002 Apr; 45(9):1942-8. PubMed ID: 11960504
[TBL] [Abstract][Full Text] [Related]
35. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
Singh P; Kaur M; Sachdeva S
J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
[TBL] [Abstract][Full Text] [Related]
36. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Emanuel S; Gruninger RH; Fuentes-Pesquera A; Connolly PJ; Seamon JA; Hazel S; Tominovich R; Hollister B; Napier C; D'Andrea MR; Reuman M; Bignan G; Tuman R; Johnson D; Moffatt D; Batchelor M; Foley A; O'Connell J; Allen R; Perry M; Jolliffe L; Middleton SA
Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256
[TBL] [Abstract][Full Text] [Related]
37. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Pavana RK; Choudhary S; Bastian A; Ihnat MA; Bai R; Hamel E; Gangjee A
Bioorg Med Chem; 2017 Jan; 25(2):545-556. PubMed ID: 27894589
[TBL] [Abstract][Full Text] [Related]
38. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
40. 2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
Gangjee A; Jain HD; Phan J; Guo X; Queener SF; Kisliuk RL
Bioorg Med Chem; 2010 Jan; 18(2):953-61. PubMed ID: 20056546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
